As PrPC is associated with prion diseases as well as Alzheimer's disease (through its interactions with APP and Aβ oligomers), knowledge gained from these studies will accelerate/enhance the development and screening of prion disease and Alzheimer's disease therapeutics. This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.